Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India

Neurology India

Volumn 55, Issue 4, 2007, Pages 408-409

  Ramasamy, Kesavan ^a   Narayan, Sunil ^a   Chanolean, Shashindran ^a   Chandrasekaran, Adithan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CYP2C9 polymorphism; Phenytoin toxicity

Indexed keywords

CYTOCHROME P450 2C9; PHENYTOIN; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ACNE; ACUTE TOXICITY; ADULT; ARTICLE; BONE MALFORMATION; BONE PAIN; CASE REPORT; CHRONIC TOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GINGIVA HYPERPLASIA; GINGIVA HYPERTROPHY; GRAND MAL SEIZURE; HIRSUTISM; HOMOZYGOSITY; HUMAN; INDIA; LYMPHADENOPATHY; OSTEOMALACIA; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TONIC CLONIC SEIZURE; TOXICOGENETICS;

EID: 36549032780     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: 10.4103/0028-3886.33300     Document Type: Article

References (9)

1. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 2003;59:707-9.
2. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data. Pharmacogenetics 2002;12:251-63.
3. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive plasma phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000;22:230-2.
4. Citerio G, Nobili A, Airoldi L, Pastorelli R, Patruno A. Severe intoxication after phenytoin infusion: A preventable pharmacogenetic adverse reaction. Neurology 2003;60:1395-6.
5. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803-8.
6. Gerson B, Bell F, Chan S. Antiepileptic agents- primidone, phenobarbital, phenytoin and carbamazepine by reversed-phase liquid chromatography. Clin Chem 1984;30:105-8.
7. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
8. Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H, et al. CYP2C polymorphism, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Science 2004;74:827-34.
9. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg 1972;34:898-906.